• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Altheos

edit

Altheos, Inc. is an early stage biopharmaceutical company based in the San Francisco Bay area focused on development of highly promising near-clinical and clinical stage novel small molecule drugs.

Altheos, Inc. completed $20MM series A financing in March 2010 led by Bay City Capital with participation from Novo A/S, Canaan Partners, Life Science Angels and Atheneos Capital. The financing will be used primarily for the development of ATS907, a selective Rho-kinase inhibitor for topical treatment of glaucoma that Altheos licensed from a Japanese pharmaceutical company. The license also includes a series of highly active compounds specifically for topical treatment for glaucoma.

Milestones

edit

• 
  Altheos added Barbara Wirostko as CMO.
  Posted 10/7/10 at 8:36pm
• 
  Altheos added Henry H. Hsu as CEO.
  Posted 4/6/10 at 3:48am
• 
  Altheos added Lester Kaplan as Chairman.
  Posted 4/6/10 at 3:48am
• 
  Altheos received $12.5M in Series A funding. (2/9/12)
  Posted 2/9/12 at 6:40pm via fiercebiotech.com
• 
  Altheos received $20M in Series A funding. (4/5/10)
  Posted 4/5/10 at 11:25am via fiercebiotech.com

Videos

Screenshots

edit

Sources

1. Glaucoma drug focus inspires $20M A round for Altheos (fiercebiotech.com) [edit]
2. Altheos grabs $12.5M more, launches glaucoma trial (fiercebiotech.com) [edit]